Daniel Faga Sells 17,679 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 17,679 shares of the business’s stock in a transaction on Friday, March 27th. The stock was sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the completion of the transaction, the chief executive officer directly owned 495,965 shares in the company, valued at $30,556,403.65. This trade represents a 3.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Daniel Faga also recently made the following trade(s):

• On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The stock was sold at an average price of $44.71, for a total transaction of $638,503.51.
• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The shares were sold at an average price of $45.11, for a total transaction of $415,102.22.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The shares were sold at an average price of $43.26, for a total transaction of $662,267.34.

AnaptysBio Stock Down 11.7%

Shares of ANAB stock opened at $57.40 on Friday. The stock has a market cap of $1.65 billion, a P/E ratio of -110.38 and a beta of 0.32. AnaptysBio, Inc. has a 52 week low of $15.40 and a 52 week high of $68.39. The company’s fifty day simple moving average is $55.30 and its two-hundred day simple moving average is $43.49.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. The company had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a stock buyback program on Friday, March 27th that permits the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization permits the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its position in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares during the last quarter. Larson Financial Group LLC raised its holdings in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in AnaptysBio by 24.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after buying an additional 263 shares during the last quarter. Bessemer Group Inc. boosted its stake in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after buying an additional 1,292 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its stake in AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the period.

Analyst Ratings Changes

A number of research analysts recently weighed in on ANAB shares. UBS Group raised their target price on shares of AnaptysBio from $70.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. HC Wainwright upped their price target on shares of AnaptysBio from $51.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Barclays lifted their price objective on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.44.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.